Pharnext SA, a biopharmaceutical company developing drug combinations based on big genomic data and artificial intelligence, announced that the European Medicines Agency (EMA) has agreed with its pediatric investigation plan (PIP) for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A). “The EMA agreement with our PIP represents a significant step forward in our efforts to bring PXT3003 to patients…